Blog
Published November 3, 2020
Executive Summary
Cell-based therapies are emerging as a promising strategy for cancer and are generating a lot of interest both academically and industrially
To date, cell therapies have been approved in the US by the Food and Drug Administration (FDA) with them showing a lot of promise in a limited number of solid tumors although they have not yet progressed to FDA approval
There have been multiple challenges involved when trying to successfully commercialize the products, but the landscape looks…
Read Now
Blog
Published November 3, 2020
Written by Tom Rutkowski and Patrick Buck…
Read Now
Webinars
Available On Demand
How has COVID-19 impacted launch performance and timing?
Pharmaceutical leaders are facing some of the toughest challenges of their careers when it comes to launching in the midst of COVID-19. With so much at stake and so much uncertainty, companies are looking for fact-based insights to power their decision-making.
Trinity has done an in-depth evaluation of the impact of COVID-19 on launch performance and timing. We have compared forecasted/expected revenue to actual revenue for products that launched within six months…
Watch Now
Webinars
Available On Demand
Forecasters in the life sciences industry are facing novel challenges in the midst of the COVID-19 pandemic. With so much at stake, and so much change, forecasting in this environment is both vital and difficult. Companies are looking for the best ways to model scenarios for the future of COVID-19 and incorporate those decisions into their forecasting and decision-making.
Key Takeaways
Insights into assumptions that are critical to projecting the future of the COVID-19 pandemic.
Examples of how different scenarios…
Watch Now
Blog
Published October 15, 2020
Written by Tom Rutkowski, Jay Galli, and Kate Watkins…
Read Now
Blog
Published September 22, 2020
Executive Summary
Although CAR-Ts are on the cutting edge of oncology treatment, they are still only approved for administration following at least two other lines of treatment
Key barriers for CAR-T migration into earlier lines include the complex logistics and site of care restrictions, a lack of comparative 3L+ and 2L clinical trial data, and reimbursement uncertainty in fee-for-service (FFS) Medicare
New opportunities to overcome these hurdles are being pursued in the form of innovative pricing and contracting strategies to…
Read Now
Case Studies
Trinity completed an early payer guidance engagement, conducting comprehensive secondary research across four inflammatory disease areas.
Geographic Scope:
Client Situation
The client wanted to gain an in-depth understanding of four inflammatory disease areas to inform early stage decision-making.
Trinity’s Solution
Trinity conducted comprehensive secondary research in the following areas:
Disease background including diagnosis, prognosis, epidemiology and unmet needsCurrent and future paradigm including lines of therapies and standard of carePipeline analysis including key therapies in development and future treatment gamechangersPricing and access landscape including pricing analysis, health…
Read Now
Blog
Published August 25, 2020
Written by Michaela Broadhurst, Olivia Gugliemini, Emily Lewis, and Tom Rutkowski…
Read Now
Case Studies
Trinity completed a P&MA assessment for a gene therapy in Leber hereditary optic neuropathy (LHON) to support BD&L decision-making.
Geographic Scope:
Client Situation
The client wanted to understand the current and future market landscape and the resulting pricing and access potential for a gene therapy asset in Leber hereditary optic neuropathy to support their BD&L decision-making.
Trinity’s Solution
Trinity conducted in-depth interview (IDI) discussions with payers and key opinion leaders (KOLs) to evaluate current treatment practices and price thresholds for LHON, and understand likely payer restrictions as a function of price.…
Read Now
Case Studies
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope:
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC…
Read Now
